Muchos de los artículos tienen comentarios en el blog que dirige el Dr. Mateu Seguí, con interesantes aportaciones de otros miembros del grupo o expertos en DM. Síguelos
Enero 2015
El umbral de HbA1c ≥ 5,9% (41 mmol/mol) sería un buen punto de corte para evitar el riesgo gestacional en la embarazada
Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care. 2014 Nov;37(11):2953-9. doi: 10.2337/dc14-1312. Epub 2014 Sep 4.
Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care. 2014 Nov;37(11):2953-9. doi: 10.2337/dc14-1312. Epub 2014 Sep 4.
¿Existen diferencias en cuanto a la mortalidad entre las sulfonilureas?
Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015 Jan;3(1):43-51.
Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015 Jan;3(1):43-51.
Actualización 2015 del Algoritmo ADA/EASD del tratamiento de la hiperglucemia
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care. 2015 Jan;38(1):140-149.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care. 2015 Jan;38(1):140-149.
A los 30 años del Diabetes Control and Complications Trial (DCCT) también se mejora la mortalidad
Writing Group for the DCCT/EDIC Research Group, Orchard TJ1, Nathan DM2, Zinman B3, Cleary P4, Brillon D5, Backlund JY4, Lachin JM4. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015 Jan 6;313(1):45-53. doi: 10.1001/jama.2014.16107.
Writing Group for the DCCT/EDIC Research Group, Orchard TJ1, Nathan DM2, Zinman B3, Cleary P4, Brillon D5, Backlund JY4, Lachin JM4. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015 Jan 6;313(1):45-53. doi: 10.1001/jama.2014.16107.
El índice de masa corporal y la mortalidad en los pacientes con diabetes tipo 2.
Tobias DK, Pan A, Jackson CL, O’Reilly EJ, Ding EL, et al. Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes. N Engl J Med2014;370:233-44.
DOI:10.1056/NEJMoa1304501
Tobias DK, Pan A, Jackson CL, O’Reilly EJ, Ding EL, et al. Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes. N Engl J Med2014;370:233-44.
DOI:10.1056/NEJMoa1304501
El péptido-C en el diagnóstico de la diabetes tipo 1. Davis AK1, DuBose SN2, Haller MJ3, Miller KM2, DiMeglio LA4, Bethin KE5, Goland RS6, Greenberg EM6, Liljenquist DR7, Ahmann AJ8, Marcovina SM9, Peters AL10, Beck RW2, Greenbaum CJ11; for the T1D Exchange Clinic Network.Prevalence of Detectable C-peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. Diabetes Care. 2014 Dec 17. pii: DC_141952. [Epub ahead of print]
La asociación entre insulina basal y los agonistas de los receptores Glucagon-like peptide. Scholz GH1, Fleischmann H2. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Ther Adv Endocrinol Metab. 2014 Oct;5(5):95-123. doi: 10.1177/2042018814556099.
Febrero 2015
Que fármaco es más efectivo en el tratamiento de la diabetes gestacional.
Balsells M1, García-Patterson A2, Solà I3, Roqué M3, Gich I4, Corcoy R5. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h102 (Published 21 January 2015)
Balsells M1, García-Patterson A2, Solà I3, Roqué M3, Gich I4, Corcoy R5. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h102 (Published 21 January 2015)
La importancia de la hipertensión arterial en el individuo con prediabetes.
Qiu M1, Shen W2, Song X1, Ju L1, Tong W1, Wang H1, Zheng S1, Jin Y1, Wu Y1, Wang W2, Tian J2. Effects of Prediabetes Mellitus Alone or Plus Hypertension on Subsequent Occurrence of Cardiovascular Disease and Diabetes Mellitus: Longitudinal Study. Hypertension. 2015 Jan 26. pii: HYPERTENSIONAHA.114.04632. [Epub ahead of print]
Qiu M1, Shen W2, Song X1, Ju L1, Tong W1, Wang H1, Zheng S1, Jin Y1, Wu Y1, Wang W2, Tian J2. Effects of Prediabetes Mellitus Alone or Plus Hypertension on Subsequent Occurrence of Cardiovascular Disease and Diabetes Mellitus: Longitudinal Study. Hypertension. 2015 Jan 26. pii: HYPERTENSIONAHA.114.04632. [Epub ahead of print]
El uso de metformina podría reducir el riesgo de trombosis venosa profunda.
Lu DY, Huang CC, Huang PH, Chung CM, Lin SJ, Chen JW, Chan WL, Leu HB1. Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord. 2014 Dec 15;14:187. doi: 10.1186/1471-2261-14-187.
Lu DY, Huang CC, Huang PH, Chung CM, Lin SJ, Chen JW, Chan WL, Leu HB1. Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord. 2014 Dec 15;14:187. doi: 10.1186/1471-2261-14-187.
¿Previene la educación sanitaria las úlceras en el pie diabético?
Dorresteijn JA1, Kriegsman DM, Assendelft WJ, Valk GD. Patient education for preventing diabetic foot ulceration. Cochrane Database Syst Rev. 2014 Dec 16;12:CD001488. doi: 10.1002/14651858.CD001488.pub5.
Dorresteijn JA1, Kriegsman DM, Assendelft WJ, Valk GD. Patient education for preventing diabetic foot ulceration. Cochrane Database Syst Rev. 2014 Dec 16;12:CD001488. doi: 10.1002/14651858.CD001488.pub5.
Los factores de riesgo modificables de la prediabetes. El estudio PREDAPS. Díaz-Redondo A, Giráldez-García C, Carrillo L, Serrano R, García-Soidán F, Artola S, Franch J, Díez J, Ezkurra P, Millaruelo J, Seguí M, Sangrós J, Martínez-Candela J, Muñoz P, Goday A, Regidor E. Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Fam Pract. 2015 Jan 22;16(1):5. [Epub ahead of print]
¿Puede la cirugía bariátrica en pacientes obesos prevenir la diabetes tipo 2? Booth H1, Khan O, Prevost T, Reddy M, Dregan A, Charlton J, Ashworth M, Rudisill C, Littlejohns P, Gulliford MC. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014 Dec;2(12):963-8.
¿Hay que tomarse en serio la disglucemia leve?
Monnier L1, Colette C2, Dejager S3, Owens DR4."Mild dysglycemia" in type 2 diabetes: to be neglected or not? J Diabetes Complications. 2014 Dec 12. pii: S1056-8727(14)00400-0. doi: 10.1016/j.jdiacomp.2014.12.004. [Epub ahead of print]
Monnier L1, Colette C2, Dejager S3, Owens DR4."Mild dysglycemia" in type 2 diabetes: to be neglected or not? J Diabetes Complications. 2014 Dec 12. pii: S1056-8727(14)00400-0. doi: 10.1016/j.jdiacomp.2014.12.004. [Epub ahead of print]
Marzo 2015
Tener la diabetes tipo 2 (DM2) se asocia con una pérdida de la esperanza de vida y un incremento de los gastos sanitarios en EEUU.
Leung MY1, Pollack LM2, Colditz GA1, Chang SH3. Life years lost and lifetime health care expenditures associated with diabetes in the U.S., National Health Interview Survey, 1997-2000.
Diabetes Care. 2015 Mar;38(3):460-8. doi: 10.2337/dc14-1453. Epub 2014 Dec 31.
Leung MY1, Pollack LM2, Colditz GA1, Chang SH3. Life years lost and lifetime health care expenditures associated with diabetes in the U.S., National Health Interview Survey, 1997-2000.
Diabetes Care. 2015 Mar;38(3):460-8. doi: 10.2337/dc14-1453. Epub 2014 Dec 31.
Tendencias en la incidencia de la diabetes tipo 2 en la cohorte de Framingham. Abraham TM1, Pencina KM2, Pencina MJ3, Fox CS4. Trends in diabetes incidence: the framingham heart study. Diabetes Care. 2015 Mar;38(3):482-7. doi: 10.2337/dc14-1432. Epub 2014 Dec 31.
Sobre la asociación de los co-transportadores 2 de la bomba sodio-glucosa y la insulina. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al and CANVAS Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.. Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.
¿Qué recomendar? ¿Ingerir menos grasas saturadas o más poliinsaturadas? Ward T. Saturated Fat and CAD: It's Complicated. the heart.org on Medscape. February 09, 2015 http://www.medscape.com/viewarticle/839360?src=wnl_int_edit_tp10&uac=143971AG
Las estatinas descienden la sensibilidad periférica y la secreción pancreática de la insulina.
Cederberg H1, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015 Mar 10. [Epub ahead of print]
Cederberg H1, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015 Mar 10. [Epub ahead of print]
Control metabólico de los pacientes con diabetes tipo 2 en España.
Alonso-Fernández M1, Mancera-Romero J2, Mediavilla-Bravo JJ3, Comas-Samper JM4, López-Simarro F5, Pérez-Unanua MP6, Iturralde-Iriso J7; on behalf of the Work Group of Diabetes SEMERGEN (Sociedad Española de Médicos de Atención Primaria). Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus. Prim Care Diabetes. 2015 Feb 13. pii: S1751-9918(15)00007-8. doi: 10.1016/j.pcd.2015.01.006. [Epub ahead of print].
Alonso-Fernández M1, Mancera-Romero J2, Mediavilla-Bravo JJ3, Comas-Samper JM4, López-Simarro F5, Pérez-Unanua MP6, Iturralde-Iriso J7; on behalf of the Work Group of Diabetes SEMERGEN (Sociedad Española de Médicos de Atención Primaria). Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus. Prim Care Diabetes. 2015 Feb 13. pii: S1751-9918(15)00007-8. doi: 10.1016/j.pcd.2015.01.006. [Epub ahead of print].
El sedentarismo es un factor independiente del ejercicio físico en los resultados de salud.
Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;162(2):123-32
Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;162(2):123-32
La glimepirida en asociación con metformina, una buena alternativa en el segundo nivel terapéutico.
Amate J1, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int J Clin Pract. 2015 Mar;69(3):292-304. doi: 10.1111/ijcp.
Amate J1, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int J Clin Pract. 2015 Mar;69(3):292-304. doi: 10.1111/ijcp.
La metformina sería inefectiva en la prevención de la diabetes tipo 2 en prediabéticos de bajo riesgo. Sussman JB1, Kent DM2, Nelson JP2, Hayward RA3. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ. 2015 Feb 19;350:h454. doi: 10.1136/bmj.h454.
Abril 2015
Nueva revisión del cribado de la Diabetes tipo 2 y de la Prediabetes de la U.S. Preventive Services Task Force (USPSTF) Selph S, MD, Dana T, MLS; Blazina I, Bougatsos C, Patel H, Chou R Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. Published online 14 April 2015 doi:10.7326/M14-2221
El consumo de huevo en la diabetes tipo 2. Virtanen JK, Mursu J, Tuomainen TP, Virtanen HE, Voutilainen S. Egg consumption and risk of incident type 2 diabetes in men: the Kuopio Ischaemic Heart Disease Risk Factor Study.Am J Clin Nutr. 2015 Apr 1. pii: ajcn104109. [Epub ahead of print]
¿Están siendo los ancianos con diabetes tipo 2 sobretratados en EEUU? Lipska KJ1, Ross JS2, Miao Y3, Shah ND4, Lee SJ5, Steinman MA5. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015 Mar;175(3):356-62. doi: 10.1001/jamainternmed.2014.7345.
Es beneficioso reducir la presión arterial por debajo de 140 mm Hg en los pacientes con diabetes tipo 2.
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015 Feb 10;313(6):603-15. doi: 10.1001/jama.2014.18574.
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015 Feb 10;313(6):603-15. doi: 10.1001/jama.2014.18574.
Las estatinas en las personas mayores. Noaman S1, Ibrahim JE2, Grenfell R3. Prescribing statins for cardiovascular disease prevention in the old: an absence of evidence and an absence of guidelines. Heart Lung Circ. 2014 Jul;23(7):619-24. doi: 10.1016/j.hlc.2014.03.002. Epub 2014 Mar 12.
Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial [published online March 23, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed.2015.0289
Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial [published online March 23, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed.2015.0289
Mayo
La combinación de metformina e inhibidores DPP-4 es más segura que con sulfonilureas. Morgan CL1, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulfonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 2014 Apr 25. doi: 10.1111/dom.12306. [Epub ahead of print]
Los IECA mejorarían la evolución de la retinopatía diabética. Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Apr;3(4):263-74.
El consumo de café disminuye la arteriosclerosis subclínica. Choi Y1, Chang Y2, Ryu S2, Cho J3, Rampal S4, Zhang Y5, Ahn J1, Lima JA6, Shin H7, Guallar E5.Coffee consumption and coronary artery calcium in young and middle-aged asymptomatic adults. Heart. 2015 May 1;101(9):686-91. doi: 10.1136/heartjnl-2014-306663. Epub 2015 Mar 2.
Sobre el riesgo de acidosis láctica con la utilización de metformina en la enfermedad renal crónica. Inzucchi SE1, Lipska KJ1, Mayo H2, Bailey CJ3, McGuire DK4. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014 Dec 24-31;312(24):2668-75. doi: 10.1001/jama.2014.15298.
Mortalidad y factores de riesgo en el paciente con diabetes. Pacilli A1, Lamacchia O2, Fontana A3, Copetti M3, Cignarelli M2, Trischitta V4, De Cosmo S1. Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. PLoS One. 2015 Apr 30;10(4):e0124536. doi: 10.1371/journal.pone.0124536. eCollection 2015.
Sobre los trastornos de la glucosa y la enfermedad de Alzheimer. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015 Apr 1;172(4):323-34. doi: 10.1176/appi.ajp.2014.14070878. Epub 2015 Feb 20.
La eficacia de los fármacos antidiabéticos en el segundo escalón terapéutico Mearns ES1, Sobieraj DM1, White CM1, Saulsberry WJ1, Kohn CG2, Doleh Y3, Zaccaro E3, Coleman CI1. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015 Apr 28;10(4):e0125879. doi: 10.1371/journal.pone.0125879. eCollection 2015.
Las complicaciones disminuyen las complicaciones en los pacientes con diabetes en EEUU Gregg EW1, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014 Apr 17;370(16):1514-23. doi: 10.1056/NEJMoa1310799.
Nuevos tratamientos en la esteatohepatitis no alcohólica. Hardy T1, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175.
Las hipoglucemias atendidas en el País Vasco. Alonso-Morán E1, Orueta JF2, Nuño-Solinís R. Incidence of severe hypoglycaemic episodes in patients with type 2 diabetes in the Basque country: impact on healthcare costs. BMC Health Serv Res. 2015 May 27;15(1):207. doi: 10.1186/s12913-015-0876-2.
Junio
Prevalencia de la retinopatía diabética en el primer nivel asistencial de Cataluña. Rodriguez-Poncelas A, Miravet-Jiménez S, Casellas A, Barrot-De La Puente JF, Franch-Nadal J, López-Simarro F, Mata-Cases M, Mundet-Tudurí X. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). Br J Ophthalmol. 2015 Jun 18. pii: bjophthalmol-2015-306683. doi: 10.1136/bjophthalmol-2015-306683.
Pauta insulínica más efectiva, ¿la basal-bolus o la premezclada?. Wang C1, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2015 May;32(5):585-94. doi: 10.1111/dme.12694. Epub 2015 Feb 13.
El primer ensayo sobre seguridad cardiovascular de los análogos agonistas de los GLP-1. Elixa (lixisenatide) Bentley-Lewis R,, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. ELIXA Investigators. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.
Recomendaciones para el manejo de la diabetes durante el Ramadán. Ibrahim M, Abu Al Magd M, Annabi FA, et al on behalf of the International Group for Diabetes and Ramadan (IGDR). Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Research and Care 2015;3: e000108. doi:10.1136/bmjdrc-2015-000108
La sitagliptina se desmarca de la tendencia en hospitalización por insuficiencia cardíaca en el Trial to Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jun 8. [Epub ahead of print]
Descenso glucémico con fármacos y riesgo de insuficiencia cardíaca. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM.Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015 May;3(5):356-66. doi: 10.1016/S2213-8587(15)00044-3. Epub 2015 Mar 17.
Consecuencias del Veteran Affairs Diabetes Trial (VADT) a los 10 años de seguimiento. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 4;372(23):2197-206. doi: 10.1056/NEJMoa1414266
Las recomendaciones de reducir el porcentaje de grasas en la dieta sin suficiente base científica. Harcombe Z, Baker JS, Cooper SM, Davies B, Sculthorpe N, DiNicolantonio JJ, Grace F. Evidence from randomised controlled trials did not support the introduction of dietary fat guidelines in 1977 and 1983: a systematic review and meta-analysis. Open Heart. 2015 Jan 29;2(1):e000196. doi: 10.1136/openhrt-2014-000196. eCollection 2015.
Julio
Productividad de los autores en el campo del tratamiento de la diabetes. Holleman F, Uijldert M, Donswijk LF, Gale EA. Productivity of authors in the field of diabetes: bibliographic analysis of trial publications. BMJ. 2015 Jul 1;351:h2638. doi: 10.1136/bmj.h2638.
Los inhibidores de la dipeptidil-peptidasa-4 estarían recomendados durante el Ramadán. Ibrahim M, Abu Al Magd M, Annabi FA, et al on behalf of the International Group for Diabetes and Ramadan (IGDR). Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Research and Care 2015;3: e000108. doi:10.1136/bmjdrc-2015-000108
El consumo habitual de refrescos con azúcar está asociado con la diabetes tipo 2. Imamura F1, O'Connor L2, Ye Z, Mursu J3, Hayashino Y4, Bhupathiraju SN, Forouhi NG. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015 Jul 21;351:h3576. doi: 10.1136/bmj.h3576.
Agosto
Las grasas trans de origen industrial aumenta el riesgo de enfermedad y muerte cardiovascular. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V5, Kishibe T, Uleryk E, Budylowski P, Schünemann H, Beyene J, Anand SS. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015 Aug 11;351:h3978. doi: 10.1136/bmj.h3978.
Los programas comunitarios basados en dieta y ejercicio son coste-efectivos para reducir la diabetes tipo 2 .Pronk NP, Remington PL, on behalf of the Community Preventive Services Task Force. Combined Diet and Physical Activity Promotion Programs for Prevention of Diabetes: Community Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015 Jul 14. doi: 10.7326/M15-1029. [Epub ahead of print]
La disfunción eréctil en edades medias de la vida se asociaría con la diabetes no diagnosticada en el varón . Skeldon SC, Detsky AS, Goldenberg SL, Law MR. Erectile Dysfunction and Undiagnosed Diabetes, Hypertension, and Hypercholesterolemia. Ann Fam Med. 2015 Jul;13(4):331-5. doi: 10.1370/afm.1816.
Setiembre
Setiembre
La sintomatología muscular en la utilización de las estatinas. Skeldon SC, Detsky AS, Goldenberg SL, Law MR. Erectile Dysfunction and Undiagnosed Diabetes, Hypertension, and Hypercholesterolemia. Ann Fam Med. 2015 Jul;13(4):331-5. doi: 10.1370/afm.1816.
Octubre
Características de los pacientes ancianos con diabetes tipo 2 de Cataluña. Barrot-de la Puente J, Mata-Cases M,, Franch-Nadal J, Mundet-Tudurí X, Casellas A, Fernandez-Real JM, Mauricio D. Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database. Int J Clin Pract. 2015 Sep 30. doi: 10.1111/ijcp.12741. [Epub ahead of print]
La glimepirida en el segundo escalón sería más coste-efectiva que los inhibidores de los DPP-4. Amate JM, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int J Clin Pract. 2015 Mar;69(3):292-304. doi: 10.1111/ijcp.12605. Epub 2015 Feb 16.
Los inhibidores DPP-4 tienen menor riesgo de insuficiencia cardíaca que las sulfonilureas según una base de datos retrospectiva. Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S, Rosano G, Pecorelli S, Pani L; OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015 Sep 21;36(36):2454-62. doi: 10.1093/eurheartj/ehv301. Epub 2015 Jun 25.
Noviembre
No existen diferencias en la pérdida de peso entre dieta bajas en grasas o en hidratos de carbono. Alexandraki I, Palacio C, Mooradian AD. Relative Merits of Low-Carbohydrate Versus Low-Fat Diet in Managing Obesity. South Med J. 2015 Jul;108(7):401-16. doi: 10.14423/SMJ.0000000000000308.
Canarias rompe la tendencia descendente de la mortalidad relacionada con la diabetes. Nuevo análisis del estudio DARIOS. Marcelino-Rodríguez I, Elosua R, Pérez , Fernández-Bergés D, Guembe MJ, Alonso TV, Félix FJ, González DA, Ortiz-Marrón H, Rigo F, Lapetra J, Gavrila D, Segura A1, Fitó M, Peñafiel , Marrugat J, León AC. On the problem of type 2 diabetes-related mortality in the Canary Islands, Spain. The DARIOS Study. Diabetes Res Clin Pract. 2015 Oct 23. pii: S0168-8227(15)00425-8. doi: 10.1016/j.diabres.2015.10.024. [Epub ahead of print]
El PREDAPS estudia el síndrome cardio-metabólico entre los pacientes con prediabetes.Giráldez-García C, Sangrós FJ, Díaz-Redondo A, Franch-Nadal J, Serrano R, Díez J, Buil-Cosiales P, García-Soidán FJ, Artola S, Ezkurra P, Carrillo L, Millaruelo JM, Seguí M, Martínez-Candela J, Muñoz P, Goday A, Regidor E; PREDAPS Study Group. Cardiometabolic Risk Profiles in Patients With Impaired Fasting Glucose and/or Hemoglobin A1c 5.7% to 6.4%: Evidence for a Gradient According to Diagnostic Criteria: The PREDAPS Study. Medicine (Baltimore). 2015 Nov;94(44):e1935. doi: 10.1097/MD.0000000000001935.
La cirugía bariátrica sigue siendo superior al tratamiento médico a los 5 años de la intervención en pacientes obesos con diabetes tipo 2. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015 Sep 5;386(9997):964-73. doi: 10.1016/S0140-6736(15)00075-6. f
Mortalidad del paciente con diabetes tipo 2. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347.
Diciembre
El tratamiento intensivo de la presión arterial aumenta la protección vascular en pacientes de riesgo. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015 Nov 7. pii: S0140-6736(15)00805-3. doi: 10.1016/S0140-6736(15)00805-3. [Epub ahead of print]